Horizon Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Horizon Therapeutics has a total shareholder equity of $5.3B and total debt of $2.6B, which brings its debt-to-equity ratio to 48.2%. Its total assets and total liabilities are $9.3B and $4.0B respectively. Horizon Therapeutics's EBIT is $644.3M making its interest coverage ratio 9.4. It has cash and short-term investments of $2.5B.
Key information
48.2%
Debt to equity ratio
US$2.56b
Debt
| Interest coverage ratio | 9.4x |
| Cash | US$2.48b |
| Equity | US$5.31b |
| Total liabilities | US$3.99b |
| Total assets | US$9.30b |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: HPR's short term assets ($3.9B) exceed its short term liabilities ($917.7M).
Long Term Liabilities: HPR's short term assets ($3.9B) exceed its long term liabilities ($3.1B).
Debt to Equity History and Analysis
Debt Level: HPR's net debt to equity ratio (1.4%) is considered satisfactory.
Reducing Debt: HPR's debt to equity ratio has reduced from 219.2% to 48.2% over the past 5 years.
Debt Coverage: HPR's debt is well covered by operating cash flow (40.7%).
Interest Coverage: HPR's interest payments on its debt are well covered by EBIT (9.4x coverage).